NEUP: Neuphoria Therapeutics Inc. Average Forecast Price
Neuphoria Therapeutics Inc. (NEUP) relies on partnerships with industry behemoths to optimize drug development, reducing costs through licensing. The business focuses on creating a safe alternative to benzodiazepines for the treatment of PTSD and anxiety. The price visualization on GURU.Markets, which assists in the basic asset valuation, captured a value of 7.00, which is relevant given the colossal demand from physicians for modern non-sedative agents.
Analytical breakdowns for Neuphoria Therapeutics Inc. (NEUP)
- stock price and consensus target price:
- market capitalization information:
- shareholders' equity book value data:
- business debt structure and liquidity details:
Debt to Equity Ratio Neuphoria Therapeutics Inc.|NEUP - Long-Term Debt to Capital|Current Liabilities to Capital bionomics.com.au|NEUP - Company Total Debt|Debts to Book Capitalization Neuphoria|NEUP - Company Long-Term Debt|Company Short-Term Loans and Borrowings Neuphoria Therapeutics|Immediate Liquidity bionomics.com.au
- company profitability and valuation multiples indicators:
NEUP - Company Net Income|Net Profit Forecast Neuphoria Therapeutics Inc.|NEUP - P/E Multiple|Projected Price to Earnings Ratio bionomics.com.au|NEUP - Price/Earnings to Growth Multiple|EV/EBITDA Multiple Neuphoria|NEUP - Profit before payment of interest, taxes and amortization|Earnings per one share for the last 12 months Neuphoria Therapeutics|NEUP - Net earnings per share (EPS TTM)|Year-over-year earnings per one share growth for the last 12 months bionomics.com.au|NEUP - Earnings per share growth in current year|Expected net earnings per share growth next year Neuphoria Therapeutics Inc.
- total revenue and sales volume data:
Summary company analytics:NEUP Neuphoria Therapeutics, Inc.
For Neuphoria Therapeutics Inc. (NEUP), whose valuation depends on the success of clinical drug trials, investment potential is determined by the balance between R&D expenditures and market expectations. The vector of analyst consensus estimates reflects the arithmetic mean of expert one-year price targets, smoothing out market noise and capturing the fundamental trend of the cost of capital given the company's reliance on regular external financing.
Competitors of Neuphoria Therapeutics Inc.
biogen.com - Broker Consensus Forecast|Analyst Consensus Forecast NBIX (Neurocrine Biosciences, Inc.)|Regencell Bioscience Ltd (RGC) - Average Forecast Price|AXSM: Consensus Target|ACAD - Analyst Consensus Forecast|Xenon Pharmaceuticals (XENE) - Price Target Chart|Forecast Levels Chart VKTX (vikingtherapeutics.com)|Price Target Chart Supernus|Broker Consensus Forecast CPRX (Catalyst Pharma)|Analyst Consensus Forecast DNLI|HRMY - Average Forecast Price|Biohaven Ltd. - Consensus Target|Analyst Consensus Forecast amylyx.com AMLX|TRVI - Price Target Chart|Fair Value Consensus PRAX (Praxis Precision Medicines Inc)|Anavex Corp (AVXL) - Price Target Chart|Average Forecast Price CeriBell EEG (CBLL)|Price Target Chart Prothena Corporation PLC|Broker Consensus Forecast ALEC (Alector Therapeutics)|Analyst Consensus Forecast ANNX|OMER - Average Forecast Price|Neurogene Corp - Consensus Target|Analyst Consensus Forecast AC Immune Inc ACIU|VYGR - Price Target Chart|Forecast Levels Chart NMRA|SCLX: Analyst Consensus Forecast|Tevogen Bio Holdings Inc. - Fair Value Consensus|Price Target Chart Alpha Cognition Inc|Average Forecast Price cogrx.com CGTX|Price Target Chart Inhibikase Therapeutics (IKT)|SAVA (cassavasciences.com) - Fair Value Consensus|Analyst Consensus Forecast ASRT (Assertio)|Analyst Median Target Coya Therapeutics Inc (COYA)|VistaGen Therapeutics Inc - Analyst Consensus Forecast|OVID - Analyst Consensus Forecast|ABOS (Acumen Pharmaceuticals) - Consensus Target|cervomed.com - Fair Value Consensus|Consensus Target ATHE|CLNN (Clene Nanomedicine) - Analyst Forecast Prices|Analyst Consensus Forecast PEPG|JUNS (jupiterneurosciences.com) - Fair Value Consensus|Analyst Consensus Forecast RLMD (Relmada Therapeutics)|annovisbio.com (ANVS) - Average Forecast Price|GRCE - Price Target Chart|Fair Value Consensus AIFF (Firefly Neuroscience, Inc.)|KLTO: Analyst Consensus Forecast|NeuroSense Therapeutics Ltd. (NRSN) - Analyst Consensus Forecast|Price Target Chart Reviva Pharmaceuticals|MetaVia, Inc. - Forecast Levels Chart|Analyst Consensus Forecast NRXS|HSDT - Average Forecast Price|Passage Bio - Consensus Target|Analyst Consensus Forecast Minerva NERV|ATHA: Consensus Target|addextherapeutics.com - Analyst Forecast Prices|ALZN: Analyst Consensus Forecast|CYCN - Analyst Median Target|PTIX (Protagenic Therapeutics Inc.) - Analyst Consensus Forecast|Consensus Target Pasithea (KTTA)|Price Target Chart Cortigent, Inc. (CRGT)|Analyst Median Target avenuetx.com|BrainStorm Cell Therapeutics - Consensus Target|Fair Value Consensus CARA|Chromocell Therapeutics Corporation - Analyst Consensus Forecast|Analyst Median Target Eliem Therapeutics ELYM|intracellulartherapies.com (ITCI) - Price Target Chart|Broker Consensus Forecast LBPH|MRNS (Marinus Pharmaceuticals, Inc.) - Analyst Consensus Forecast|Consensus Target NKGen Biotech Inc (NKGN)|Consensus Target NRBO (NeuroBo)|Analyst Median Target Sage Therapeutics Inc|Price Target Chart Synaptogenix, Inc. SNPX|TRVN: Broker Consensus Forecast|Vigil Neuro - Analyst Consensus Forecast|Average Forecast Price Anew Medical Inc.|CERE (Cerevel) - Consensus Target
